RxDoctor Payments Data

Kyle Hulme, MD

Family Medicine · Waco, TXNPI 1649360421

Payments from drug & device makers

$9,693in general payments, 2019–2025

Across 642 payments — averaging $15.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$826
  • Pfizer$797
  • Lilly USA, LLC$705
  • GSK$592
  • AstraZeneca$502
  • plus $5K from 43 others

What the payments were for

  • Food & beverage$9,674100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,693 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$123,906
Medicare patients
185
Services billed
3,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide79$81,056
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$27,477
EliquisApixaban22$18,729
MounjaroTirzepatide18$18,685
JardianceEmpagliflozin18$17,124
MyrbetriqMirabegron23$9,489
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$8,754
Tresiba Flextouch U-200Insulin Degludec14$8,401
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$7,601
BelsomraSuvorexant14$7,020
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,677
JanumetSitagliptin Phos/Metformin Hcl12$6,444
Celecoxib156$4,937
Incruse ElliptaUmeclidinium Bromide12$4,171
Colesevelam Hcl24$3,936

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$826$81,05679 claims
GSKTrelegy Ellipta, Incruse Ellipta$592$31,64847 claims
PfizerEliquis, Paxlovid$797$20,15845 claims
Lilly USA, LLCMounjaro$705$18,68518 claims
Boehringer IngelheimJardiance$236$17,12418 claims
MerckBelsomra, Janumet$374$13,46426 claims
Astellas Pharma US IncMyrbetriq$480$9,48923 claims
AstraZenecaBreztri Aerosphere$502$6,67711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →